- Home
- NUVL vs EPRT Comparison
NUVL vs EPRT Comparison
Compare NUVL & EPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- EPRT
- Stock Information
- Founded
- NUVL 2017
- EPRT 2016
- Country
- NUVL United States
- EPRT United States
- Employees
- NUVL N/A
- EPRT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- EPRT Real Estate Investment Trusts
- Sector
- NUVL Health Care
- EPRT Real Estate
- Exchange
- NUVL Nasdaq
- EPRT Nasdaq
- Market Cap
- NUVL 5.6B
- EPRT 6.0B
- IPO Year
- NUVL 2021
- EPRT 2018
- Fundamental
- Price
- NUVL $73.48
- EPRT $31.71
- Analyst Decision
- NUVL Strong Buy
- EPRT Buy
- Analyst Count
- NUVL 8
- EPRT 14
- Target Price
- NUVL $115.50
- EPRT $34.84
- AVG Volume (30 Days)
- NUVL 682.1K
- EPRT 1.9M
- Earning Date
- NUVL 05-08-2025
- EPRT 04-23-2025
- Dividend Yield
- NUVL N/A
- EPRT 3.74%
- EPS Growth
- NUVL N/A
- EPRT N/A
- EPS
- NUVL N/A
- EPRT 1.16
- Revenue
- NUVL N/A
- EPRT $475,463,000.00
- Revenue This Year
- NUVL N/A
- EPRT $19.47
- Revenue Next Year
- NUVL N/A
- EPRT $17.22
- P/E Ratio
- NUVL N/A
- EPRT $27.26
- Revenue Growth
- NUVL N/A
- EPRT 25.32
- 52 Week Low
- NUVL $55.54
- EPRT $25.60
- 52 Week High
- NUVL $113.51
- EPRT $34.88
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- EPRT 51.04
- Support Level
- NUVL $71.60
- EPRT $31.39
- Resistance Level
- NUVL $74.28
- EPRT $32.67
- Average True Range (ATR)
- NUVL 4.86
- EPRT 1.13
- MACD
- NUVL 1.08
- EPRT 0.11
- Stochastic Oscillator
- NUVL 95.73
- EPRT 81.64
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About EPRT Essential Properties Realty Trust Inc.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.